Clinical Trial Update: A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH [Phase 2]

View source ↗

Summary

Phase IIa trial evaluating subcutaneous pegcetacoplan (APL-2) for safety, efficacy, and pharmacokinetics in patients with paroxysmal nocturnal hemoglobinuria (P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Pegcetacoplan (Pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: PNH | Phase 2 | Status: COMPLETED | Results posted: 2020-12-22